Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Utilizing Nanobody Technology to Target Non-Immunodominant Domains of VAR2CSA

Open access

Abstract

Placental malaria is a major health problem for both pregnant women and their fetuses in malaria endemic regions. It is triggered by the accumulation of Plasmodium falciparum-infected erythrocytes (IE) in the intervillous spaces of the placenta and is associated with foetal growth restriction and maternal anemia. IE accumulation is supported by the binding of the parasite-expressed protein VAR2CSA to placental chondroitin sulfate A (CSA). Defining specific CSA-binding epitopes of VAR2CSA, against which to target the immune response, is essential for the development of a vaccine aimed at blocking IE adhesion. However, the development of a VAR2CSA adhesion-blocking vaccine remains challenging due to (i) the large size of VAR2CSA and (ii) the extensive immune selection for polymorphisms and thereby non-neutralizing B-cell epitopes. Camelid heavy-chain-only antibodies (HcAbs) are known to target epitopes that are less immunogenic to classical IgG and, due to their small size and protruding antigen-binding loop, able to reach and recognize cryptic, conformational epitopes which are inaccessible to conventional antibodies. The variable heavy chain (VHH) domain is the antigen-binding site of camelid HcAbs, the so called Nanobody, which represents the smallest known (15 kDa) intact, native antigen-binding fragment. In this study, we have used the Nanobody technology, an approach new to malaria research, to generate small and functional antibody fragments recognizing unique epitopes broadly distributed on VAR2CSA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0084981

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Sequence alignment of the 17 VAR2CSA-specific Nbs. The clones used for Nanobody production were sequenced, converted to amino acid sequences and aligned. The complementarity determining regions (CDRs) 1–3 make up the binding paratope and the framework regions (FRs) 1–4 are indicated.
Figure 1 Sequence alignment of the 17 VAR2CSA-specific Nbs. The clones used for Nanobody production were sequenced, converted to amino acid sequences and aligned. The complementarity determining regions (CDRs) 1–3 make up the binding paratope and the framework regions (FRs) 1–4 are indicated.CC BY · PubMed Central
Figure 2 Recognition of immobilized full-length VAR2CSA by each of the 17 Nbs. Microtiter plates were coated with VAR2CSA protein (50 nM) and incubated with individual Nbs (50 nM). Binding was detected with rabbit anti-camel antibody and HRP-conjugated goat anti-rabbit antibody. Optical density was measured at 490 nm after 20 min. A non-VAR2CSA-PfEMP1 (50 nM) was used as negative control. Data are represented as mean and standard deviations of three independent experiments.
Figure 2 Recognition of immobilized full-length VAR2CSA by each of the 17 Nbs. Microtiter plates were coated with VAR2CSA protein (50 nM) and incubated with individual Nbs (50 nM). Binding was detected with rabbit anti-camel antibody and HRP-conjugated goat anti-rabbit antibody. Optical density was measured at 490 nm after 20 min. A non-VAR2CSA-PfEMP1 (50 nM) was used as negative control. Data are represented as mean and standard deviations of three independent experiments.CC BY · PubMed Central
Figure 3 Recognition of immobilized VAR2CSA domains by Nbs (Nb01–Nb17). Baculovirus-produced domains of VAR2CSA (50 nM) were coated on microtiter plates and incubated with each of the Nbs (50 nM). The binding was detected with rabbit anti-camel and goat anti-rabbit HRP-conjugated antibodies and optical density measured at 490 nm after 20 min. Non-VAR2CSA PfEMP1 (50 nM) was used as negative control. The assay was performed several times with similar result.
Figure 3 Recognition of immobilized VAR2CSA domains by Nbs (Nb01–Nb17). Baculovirus-produced domains of VAR2CSA (50 nM) were coated on microtiter plates and incubated with each of the Nbs (50 nM). The binding was detected with rabbit anti-camel and goat anti-rabbit HRP-conjugated antibodies and optical density measured at 490 nm after 20 min. Non-VAR2CSA PfEMP1 (50 nM) was used as negative control. The assay was performed several times with similar result.CC BY · PubMed Central
Figure 4 Recognition of the minimal CSA-binding region of VAR2CSA. (A) Reactivity of Nbs to specific minimal CSA-binding regions produced in different expression systems. ID1–ID2a proteins produced either in a baculo–virus expression system (BV), or in E. coli (coli) or in Schneider 2 (S2) cells were coated (50 nM) on microtiter plates and incubated with 50 nM Nb01, Nb07, Nb09, Nb10 or Nb12 (Nbs specific for VAR2CSA minimal CSA-binding domain). Nb02 (DBL5-specific) was used as a negative control. (B) Cross-reacitivity of Nbs specific for the minimal CSA-binding region of FCR3 to recombinant proteins covering the minimal CSA-binding region (DBL1-ID2a and ID1–ID2a) of the heterologous 3D7 parasite line produced in the baculovirus expression system. In both assays, the binding was detected with rabbit-anti-camel antibody and HRP-labeled goat anti-rabbit antibody and the optical density was measured at 490 nm after 20 min. A non-VAR2CSA protein was used as a negative control.
Figure 4 Recognition of the minimal CSA-binding region of VAR2CSA. (A) Reactivity of Nbs to specific minimal CSA-binding regions produced in different expression systems. ID1–ID2a proteins produced either in a baculo–virus expression system (BV), or in E. coli (coli) or in Schneider 2 (S2) cells were coated (50 nM) on microtiter plates and incubated with 50 nM Nb01, Nb07, Nb09, Nb10 or Nb12 (Nbs specific for VAR2CSA minimal CSA-binding domain). Nb02 (DBL5-specific) was used as a negative control. (B) Cross-reacitivity of Nbs specific for the minimal CSA-binding region of FCR3 to recombinant proteins covering the minimal CSA-binding region (DBL1-ID2a and ID1–ID2a) of the heterologous 3D7 parasite line produced in the baculovirus expression system. In both assays, the binding was detected with rabbit-anti-camel antibody and HRP-labeled goat anti-rabbit antibody and the optical density was measured at 490 nm after 20 min. A non-VAR2CSA protein was used as a negative control.CC BY · PubMed Central
Figure 5 Nbs recognize both continuous and discontinuous epitopes. Reduced and non-reduced baculovirus-produced VAR2CSA domains were transferred onto membranes by Western blotting and probed with the corresponding domain-specific Nbs; (A) DBL4ε protein probed with Nb03, Nb13, Nb16 and Nb17. (B) DBL5ε protein probed with Nb02, Nb05, Nb11, Nb14. (C) DBL6ε probed with Nb15, Nb08, Nb06 and Nb04. (D) DBL1-ID2a protein (containing minimal CSA-binding region) probed with Nb12, Nb10, Nb09, Nb07 and Nb01. Binding was detected with rabbit-anti-camel and HRP-labeled goat-anti-rabbit antibodies. Bands larger than monomer size correspond to multimers formed by intermolecular disulfide bonds (monomers are marked with arrows).
Figure 5 Nbs recognize both continuous and discontinuous epitopes. Reduced and non-reduced baculovirus-produced VAR2CSA domains were transferred onto membranes by Western blotting and probed with the corresponding domain-specific Nbs; (A) DBL4ε protein probed with Nb03, Nb13, Nb16 and Nb17. (B) DBL5ε protein probed with Nb02, Nb05, Nb11, Nb14. (C) DBL6ε probed with Nb15, Nb08, Nb06 and Nb04. (D) DBL1-ID2a protein (containing minimal CSA-binding region) probed with Nb12, Nb10, Nb09, Nb07 and Nb01. Binding was detected with rabbit-anti-camel and HRP-labeled goat-anti-rabbit antibodies. Bands larger than monomer size correspond to multimers formed by intermolecular disulfide bonds (monomers are marked with arrows).CC BY · PubMed Central
Figure 6 Nanobody recognition of native VAR2CSA expressed on the surface of P. falciparum-infected erythrocytes (IE). Binding of VAR2CSA-specific Nbs to VAR2CSA-expressing IE was measured by flow cytometry. Three different P. falciparum strains (FCR3, 7201 and NF54) were tested. Each bar represents reactivity of 25 µl nanobody (0.1 mg/ml) to 50 µl IE (2×105 parasites/ml). Values are normalized to the mean fluorescence intensity (MFI) of the negative control (neg ctr; IE incubated only with the secondary and tertiary antibodies). Specific recognition was defined by an MFI ratio >1.2. Error bars in A) represents standard deviation of three independent experiments.
Figure 6 Nanobody recognition of native VAR2CSA expressed on the surface of P. falciparum-infected erythrocytes (IE). Binding of VAR2CSA-specific Nbs to VAR2CSA-expressing IE was measured by flow cytometry. Three different P. falciparum strains (FCR3, 7201 and NF54) were tested. Each bar represents reactivity of 25 µl nanobody (0.1 mg/ml) to 50 µl IE (2×105 parasites/ml). Values are normalized to the mean fluorescence intensity (MFI) of the negative control (neg ctr; IE incubated only with the secondary and tertiary antibodies). Specific recognition was defined by an MFI ratio >1.2. Error bars in A) represents standard deviation of three independent experiments.CC BY · PubMed Central
Figure 7 Adhesion-inhibitory capacity of VAR2CSA-specific nanobodies. (A) Ability of the individual Nbs to inhibit the adhesion of VAR2CSA-expressing IE (FCR3 line) to Decorin. Nbs specific for the minimal CSA-binding-region of VAR2CSA (Nb01, Nb07, Nb09, Nb10 and Nb12) were tested three times on the homologous parasite FCR3-CSA. (B) Adhesion inhibition capacity of the minimal CSA-binding-specific Nbs to VAR2CSA-expressing heterologous parasite lines NF54 and (C) 7201. Parasite binding to CSA ligand without Nbs was set to 100.
Figure 7 Adhesion-inhibitory capacity of VAR2CSA-specific nanobodies. (A) Ability of the individual Nbs to inhibit the adhesion of VAR2CSA-expressing IE (FCR3 line) to Decorin. Nbs specific for the minimal CSA-binding-region of VAR2CSA (Nb01, Nb07, Nb09, Nb10 and Nb12) were tested three times on the homologous parasite FCR3-CSA. (B) Adhesion inhibition capacity of the minimal CSA-binding-specific Nbs to VAR2CSA-expressing heterologous parasite lines NF54 and (C) 7201. Parasite binding to CSA ligand without Nbs was set to 100.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 31

Metadata

Authors
Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A.
Affiliations
  • University of Copenhagen (DK)
  • Vrije Universiteit Brussel (BE)
  • The Royal Melbourne Hospital (AU)
Corresponding author
Ditlev, Sisse B.
Venue
PLoS ONE
Published
2014-01-21
Volume
9
Issue
1
Pages
e84981
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2043051805
Cited by
31
References
37
Citations by year
2026: 3 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 5
FWCI
4.31
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Højteknologifonden
  • Agentschap voor Innovatie door Wetenschap en Technologie
  • Novo Nordisk
  • Novo Nordisk Fonden
  • National Health and Medical Research Council (1003384)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
Keywords
VAR2CSA, placental malaria, Plasmodium falciparum, chondroitin sulfate A, nanobodies, VHH, heavy-chain antibodies, epitope mapping, infected erythrocyte adhesion, placenta, conformational epitopes
MeSH terms
Amino Acid Sequence, Animals, Epitopes, Antigens, Protozoan, Camelids, New World, Chondroitin Sulfates, Erythrocytes, Humans, Immunoglobulin Heavy Chains, Molecular Sequence Data, Plasmodium falciparum, Protein Binding, Recombinant Proteins, Sequence Alignment, Malaria, Falciparum, Peptide Library, Single-Domain Antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Utilizing Nanobody Technology to Target Non-Immunodominant Domains of VAR2CSA. https://app.cochat.ai/papers/10.1371/journal.pone.0084981
The paper
Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A. (2014). Utilizing Nanobody Technology to Target Non-Immunodominant Domains of VAR2CSA. PLoS ONE. https://doi.org/10.1371/journal.pone.0084981

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.